Published: September 27, 2021 Abstract: Introduction: Cannabigerol (CBG), and its precursor before decarboxylation, cannabigerolic acid is sometimes labeled the ‘‘mother of all cannabinoids.’’ The purpose of the present study was to investigate reasons for use and...
Research
Medical Conditions & Cannabis
Meta-Analysis of Cannabigerol Effects on Breast Cancer Tissue Cells
Published: May 4, 2021 Abstract: Cannabigerol (CBG) is one of over 120 cannabinoids known that is produced by the Cannabis sativa plant and has become of recent therapeutic interest. Cannabinoids target primarily cannabinoid receptors 1 and 2 (CBR1/CBR2) and form...
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis derived non-psychotropic cannabinoid
Published: September 30, 2014 Abstract: Cannabigerol (CBG) is a safe non-psychotropic Cannabis-derived cannabinoid (CB), which interacts with specific targets involved in carcinogenesis. Specifically, CBG potently blocks transient receptor potential (TRP) M8 (TRPM8),...
Cannabidiol—from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer
Published: November 25, 2019 Abstract: Cannabis sativa L. is a plant long used for its textile fibers, seed oil, and oleoresin with medicinal and psychoactive properties. It is the main source of phytocannabinoids, with over 100 compounds detected so far. In recent...
Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype
Published: December 28, 2021 Abstract: Although cannabinoids have been used for centuries for diverse pathological conditions, recently, their clinical interest and application have emerged due to their diverse pharmacological properties. Indeed, it is well...
Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
Published: February 5, 2021 Abstract: Glioblastoma is the most aggressive cancer among primary brain tumors. As with other cancers, the incidence of glioblastoma is increasing; despite modern therapies, the overall mean survival of patients' post-diagnosis averages...
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
Published: March 10, 2021 Abstract: The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV2 infection. CBD and its metabolite, 7-OH-CBD, but not...
Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants
Published: January 10, 2022 Abstract: As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity...
The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders
Published: February, 2020 Abstract: Mood disorders are the most prevalent mental conditions encountered in psychiatric practice. Numerous patients suffering from mood disorders present with treatment-resistant forms of depression, co-morbid anxiety, other psychiatric...
Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio Harveyi
Published: May 7, 2021 Abstract: Cannabigerol (CBG) is a non-psychoactive cannabinoid naturally present in trace amounts in the Cannabis plant. So far, CBG has been shown to exert diverse activities in eukaryotes. However, much less is known about its effects on...